Gland Pharma
- Market cap
- ₹ 46,669 Cr.
- P/E
- 43.9x
- P/B
- 4.53x
- 52-week range
- 1,573.6 – 3,171
- ROE
- 11%
- ROCE
- 15%
- Dividend yield
- 0.7%
- Debt / equity
- 0.03
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a range of dosage formulations, including solutions, suspensions, and lyophilized products. Its product portfolio includes delivery methods such as pre-filled syringes, vials, ampoules, bags, and dry powder injections. It also produces generic injectables in liquid, lyophilized, suspension, and pre-filled syringe forms. Its molecules include Enoxaparin Sodium, Cisplatin, Lacosamide, Rocuronium Bromide, Zoledronic Acid, Vancomycin, and others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynecological, Hormones, and others. The Company functions primarily on a business-to-business model. Its subsidiary is Gland Pharma International Pte. Ltd.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Gland Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)43.9 against a typical 34.3: pricier than most peers (1st = cheapest).141st of 220
- Sales growth+19.5% against a typical +15.6% from a year earlier.83rd of 197
- Profit growth+47.4% against a typical +18.9% from a year earlier.55th of 160
- Share price, 3 months+19.6% against a typical −0.5%.36th of 200
- Size₹ 46,669 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).15th of 199
Latest announcements
Exchange filings and their impact on the company.
- Dundigal USFDA inspection ends with 4 minor procedural observations, no data-integrity issues.
Gland Pharma said the USFDA conducted an unannounced cGMP inspection at its Dundigal formulation facility from October 12 to October 23, 2026. The inspection closed with four Form 483 observations described as procedural in nature, with no repeat observations and no data-integrity issues. The company will submit corrective and preventive actions within the stipulated period, indicating business as usual with no plant action expected.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 6 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 10 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 15 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 28 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 3 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 5 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 20 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,373 | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 |
| Expenses | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 | 1,311 |
| Operating Profit | 324 | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 |
| OPM % | 24% | 23% | 23% | 19% | 21% | 26% | 24% | 24% | 21% | 26% | 29% | 27% |
| Other Income | 53 | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 39 | 111 | 61 |
| Interest | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 |
| Depreciation | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 |
| Profit before tax | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 |
| Tax % | 33% | 32% | 35% | 34% | 36% | 32% | 35% | 31% | 35% | 28% | 28% | 27% |
| Net Profit | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| EPS in Rs | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | 19.21 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 13%
- 3 Years
- 21%
- TTM
- 18%
- 10 Years
- —
- 5 Years
- 1%
- 3 Years
- 8%
- TTM
- 49%
- 10 Years
- —
- 5 Years
- −7%
- 3 Years
- 21%
- TTM
- —
- 10 Years
- —
- 5 Years
- 11%
- 3 Years
- 9%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Gland Pharma | ₹ 3,043.00 | ₹ 46,669 Cr. | 43.9x | 4.5x | 11% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Srinivas Sadu
- Executive Chairman of the Board
- Ravi Shekhar Mitra
- Chief Financial Officer
- Sampath Kumar Pallerlamudi
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.